ACLX Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of -39.02%. Arcellx, Inc.'s return on equity of -49.8% beat Geron Corp.'s return on equity of -29.65%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 71.51%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 157.14%. Given that Geron Corp. has higher upside potential than Arcellx, Inc., analysts believe Geron Corp. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Geron Corp. quarterly revenues of $47.2M. Arcellx, Inc.'s net income of -$55.8M is lower than Geron Corp.'s net income of -$18.4M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.31x versus 5.08x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 39.21%. Arcellx, Inc.'s return on equity of -49.8% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 71.51%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.34%. Given that Arcellx, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Arcellx, Inc. is more attractive than Gilead Sciences, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Arcellx, Inc.'s net income of -$55.8M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.31x versus 5.44x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 21.47%. Arcellx, Inc.'s return on equity of -49.8% beat Johnson & Johnson's return on equity of 33.27%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 71.51%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.73%. Given that Arcellx, Inc. has higher upside potential than Johnson & Johnson, analysts believe Arcellx, Inc. is more attractive than Johnson & Johnson.

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.47% to investors and pays a quarterly dividend of $1.30 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Arcellx, Inc.'s net income of -$55.8M is lower than Johnson & Johnson's net income of $5.2B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.31x versus 5.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 38.89%. Arcellx, Inc.'s return on equity of -49.8% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Arcellx, Inc. has a consensus price target of $112.35, signalling upside risk potential of 71.51%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $788.28 which suggests that it could grow by 0.58%. Given that Arcellx, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Arcellx, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Arcellx, Inc.'s net income of -$55.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 102.31x versus 6.06x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.